Hardman Johnston Global Advisors LLC Cuts Stock Position in Medtronic PLC $MDT

Key Points

• Hardman Johnston Global Advisors trimmed its Medtronic stake by 15.4% in Q4, selling 36,295 shares and now holding 198,864 shares valued at about $19.1 million.
• Medtronic beat quarterly estimates (EPS $1.36 vs $1.34; revenue $9.02B vs $8.89B) and set FY2026 guidance of $5.62–$5.66 EPS
• The company declared a quarterly dividend of $0.71 (annualized $2.84, ~3.3% yield; ex-dividend March 27) while EVP Harry Skip Kiil sold 52,524 shares, reducing his stake by 61.6%.

Hardman Johnston Global Advisors LLC trimmed its stake in shares of Medtronic PLC (NYSE:MDT - Free Report) by 15.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 198,864 shares of the medical technology company's stock after selling 36,295 shares during the quarter. Hardman Johnston Global Advisors LLC's holdings in Medtronic were worth $19,103,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Corundum Trust Company INC bought a new position in Medtronic during the 3rd quarter worth approximately $27,000. Lodestone Wealth Management LLC bought a new position in Medtronic during the 4th quarter worth approximately $27,000. Board of the Pension Protection Fund bought a new position in Medtronic during the 4th quarter worth approximately $29,000. GoalVest Advisory LLC bought a new position in Medtronic during the 4th quarter worth approximately $29,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Medtronic in the 3rd quarter worth approximately $29,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Stock Down 0.1%

MDT stock opened at $87.17 on Monday. Medtronic PLC has a twelve month low of $79.93 and a twelve month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a market cap of $111.91 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.26 and a beta of 0.75. The business has a 50 day moving average of $93.08 and a 200 day moving average of $95.97.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts' consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic's dividend payout ratio (DPR) is 79.11%.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their target price on Medtronic from $105.00 to $95.00 and set a "hold" rating for the company in a report on Monday, April 6th. Argus decreased their target price on Medtronic from $125.00 to $115.00 and set a "buy" rating for the company in a report on Monday, April 6th. UBS Group restated a "neutral" rating and set a $104.00 target price on shares of Medtronic in a report on Wednesday, February 4th. Wells Fargo & Company initiated coverage on Medtronic in a report on Friday, January 30th. They set an "overweight" rating and a $114.00 target price for the company. Finally, Mizuho upgraded Medtronic to a "strong-buy" rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $109.00.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.26% of the company's stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.